What were the key takeaways from Cencora's earnings call?

What is Cencora's gross profit margin?

Did Cencora beat or miss consensus estimates last quarter?

What does Cencora do and what are its main business segments?

What is Cencora's latest dividend and current dividend yield?

What were the key takeaways from Cencora’s earnings call?

What factors drove the changes in Cencora's revenue and profit?

What is the market's earnings forecast for Cencora next quarter?

- **Revenue Growth**: FY 2025 revenue up 9% to $321.3B, driven by 10% U.S. Healthcare Solutions growth and 6% International expansion.
- **EPS Guidance**: FY 2026 EPS $17.45-$17.75 (9%-11% growth), supported by specialty investments and $1B infrastructure spend.
- **Strategic Shifts**: 'Other' segment (MWI, Profarma) under strategic review; U.S. Healthcare Solutions focused on MSO and specialty with 6%-9% long-term AOI guidance.
- **MSO Momentum**: RCA and OneOncology driving 25% Q4 U.S. Healthcare Solutions AOI growth; full OneOncology ownership to enhance clinical trial access.
- **International Recovery**: World Courier specialty logistics rebounded; PharmaLex refocused on core services with 5%-8% long-term growth.

**【CEO Summary Section】**
- Fiscal 2025 revenue grew 9% to $321.3 billion, driven by 10% U.S. Healthcare Solutions segment growth and 6% International Healthcare Solutions growth.
- Raised long-term adjusted operating income guidance to 6%-9% and EPS to 9%-13%, reflecting specialty leadership and MSO platform investments.
- Announced $1 billion infrastructure investment through 2030 for specialty distribution, including a second National Distribution Center.
- Strategic review resulted in 'other' segment (MWI, Profarma, legacy consulting) being evaluated for alternatives, with U.S. Healthcare Solutions now focused on specialty and MSO growth.

**【CFO Financial Commentary】**
- Q4 2025 adjusted diluted EPS: $3.84 (15% YoY growth), driven by U.S. Healthcare Solutions operating income up 25% to $872 million.
- FY 2025 free cash flow: $3 billion; FY 2026 guidance: $3 billion with $900M capex for infrastructure.
- FY 2026 guidance: EPS $17.45-$17.75 (9%-11% growth), U.S. Healthcare Solutions AOI 9%-11%, International 5%-8%.
- Interest expense: $315M-$335M due to RCA acquisition debt; effective tax rate 20%-21%.

**【Q&A Highlights】**
- **MSO Strategy**: Full OneOncology ownership expected to enhance clinical trial access and revenue cycle management. RCA's specialty logistics and oncology growth exceeded expectations.
- **Specialty Growth**: U.S. Healthcare Solutions specialty revenue growth offset generic deflation, with GLP-1 contribution moderating to 40bps in Q4.
- **International Recovery**: World Courier specialty logistics rebounded, while PharmaLex refocused on core services (pharmacovigilance, market access).
- **Capital Allocation**: 3%-4% EPS contribution from M&A; FY 2026 share buybacks ~$1B targeting 194M diluted shares.
- **Risk Management**: FY 2026 headwinds include 3Q loss of oncology customer and RCA lapping, offset by specialty infrastructure investments.

COR

COR fundamentals

You can ask Aime